Perspective: Why sole-supplier vaccine markets may be here to stay - Vaccine markets tend to evolve toward a single dominant supplier, which has advantages as well as disadvantages

Health Affairs

Volumn 24, Issue 3, 2005, Pages 694-696

  Danzon, Patricia ^a   Pereira, Nuno Sousa ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; VACCINE;

COMPETITION; CONSUMER; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; SHORT SURVEY; ARTICLE; ORGANIZATION AND MANAGEMENT; UNITED STATES;

DRUG INDUSTRY; HUMANS; UNITED STATES; VACCINES;

EID: 20044378351     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.3.694     Document Type: Short Survey

References (2)

1. M.V. Pauly, "Improving Vaccine Supply and Development: Who Needs What?" Health Affairs 24, no. 3 (2005): 680-689.
2. P.M. Danzon, N.S. Pereira, and S.S. Tejwani, "Vaccine Supply: A Cross-National Perspective," Health Affairs 24, no. 3 (2005): 706-717.